Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Lisdexamfetamine
Drug ID BADD_D02440
Description Also known as _Vyvanse_, lisdexamfetamine (L-lysine-d-amphetamine) is a prodrug of the psychostimulant d-amphetamine [A40246]. It is paired with the essential amino acid _L-lysine_. Lisdexamfetamine dimesylate increases attention span and decreases restlessness in children and adults who are overactive/hyperactive, cannot concentrate for long periods, or are easily distracted or impulsive [A2230]. As a central nervous system stimulant, lisdexamfetamine is utilized as an adjunct therapy in the treatment of attention deficit hyperactivity disorder (ADHD). As a prodrug, lisdexamfetamine was specifically engineered as an abuse-resistant product [F2368]. The mechanism by which this occurs is through delayed release after ingestion (unlike some other psychostimulant drugs, which may be abused). After oral administration and absorption, enzyme hydrolysis after contact with red blood cells metabolize lisdexamfetamine into L- lysine, a naturally occurring essential amino acid and active _d-amphetamine_, which is responsible for the drug’s pharmacological effects. Gastrointestinal pH does not affect this conversion, and the addition of the L-lysine slows the amount of d-amphetamine available in the circulation and central nervous system [F2368].
Indications and Usage For the treatment of Attention-deficit/hyperactivity disorder (ADHD) and for moderate to severe binge eating disorder in adults [FDA label], [A40246]. This drug is not indicated for weight loss. Use of other sympathomimetic drugs for weight loss is associated with serious cardiovascular effects. The safety and effectiveness of this drug for the treatment of obesity have not yet been determined [FDA label].
Marketing Status Not Available
ATC Code N06BA12
DrugBank ID DB01255
KEGG ID D08130
MeSH ID D000069478
PubChem ID 11597698
TTD Drug ID D00DEF
NDC Product Code Not Available
Synonyms Lisdexamfetamine Dimesylate | Dimesylate, Lisdexamfetamine | Lis-dexamfetamine Dimesylate | Dimesylate, Lis-dexamfetamine | Lis dexamfetamine Dimesylate | Vyvanse | Elvanse | Lisdexamfetamine | NRP104 | NRP-104 | NRP 104
Chemical Information
Molecular Formula C15H25N3O
CAS Registry Number 608137-32-2
SMILES CC(CC1=CC=CC=C1)NC(=O)C(CCCCN)N
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal discomfort07.01.06.001--Not Available
Abdominal pain07.01.05.002--
Abdominal pain upper07.01.05.0030.005018%
Acne23.02.01.0010.002266%Not Available
Aggression19.05.01.0010.006475%Not Available
Agitation19.06.02.001; 17.02.05.0120.003885%
Alcoholism19.07.02.0010.000647%Not Available
Alopecia23.02.02.0010.002590%
Amnesia19.20.01.001; 17.03.02.0010.000647%
Anger19.04.02.0010.004694%Not Available
Angina pectoris24.04.04.002; 02.02.02.0020.000647%
Angioedema23.04.01.001; 10.01.05.009--Not Available
Antisocial behaviour19.05.01.0100.000809%Not Available
Anxiety19.06.02.0020.012140%
Apathy19.04.04.0020.000647%Not Available
Aphthous ulcer07.05.06.0020.000324%Not Available
Arrhythmia02.03.02.0010.001133%Not Available
Arthralgia15.01.02.001--
Arthritis15.01.01.0010.000324%
Arthropathy15.01.01.0030.000486%Not Available
Asthenia08.01.01.001--Not Available
Atrial fibrillation02.03.03.002--
Atrioventricular block02.03.01.0020.000324%Not Available
Attention deficit/hyperactivity disorder19.21.04.0010.001781%Not Available
Back pain15.03.04.005--
Basedow's disease10.04.08.004; 06.09.04.003; 05.02.02.0030.000324%Not Available
Benign intracranial hypertension17.07.02.0010.000324%Not Available
Blepharospasm17.17.02.001; 06.05.01.0010.000324%Not Available
Blister23.03.01.001; 12.01.06.0020.000486%Not Available
Blood cholesterol increased13.12.01.0020.000324%
The 1th Page    1 2 3 4 5    Next   Last    Total 11 Pages